Therapeutic Response

ABL1 p.T315I and BCR::ABL1 status confers therapeutic sensitivity to Asciminib in patients with Chronic Myeloid Leukemia, BCR-ABL1+.

Statements

Source and description
Scemblix (asciminib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation.
Scemblix (asciminib) [product information]. EMA. The European Medicines Agency (EMA) has authorized asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) with the T315I variant who are resistant to, intolerant to, or ineligible for ponatinib.